PREventative Study Against URate-Lowering Drug-Induced Gout Exacerbations (PRE-SURGE 2)
A Multi-Center, Randomized, Double-Blind, Placebo Controlled Study of the Efficacy and Safety of Rilonacept for the Prophylaxis of Gout Flares During the Initiation of Allopurinol Therapy
Sponsor: Regeneron Pharmaceuticals
A PHASE3 clinical study on Gout, this trial is completed. The trial is conducted by Regeneron Pharmaceuticals and has accumulated 10 data snapshots since 2009. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
10 versions recorded-
Jan 2026 — Present [monthly]
Completed PHASE3
-
Dec 2025 — Present [monthly]
Completed PHASE3
-
Sep 2025 — Dec 2025 [monthly]
Completed PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
▶ Show 5 earlier versions
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE3
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE3
-
Jun 2017 — Jun 2018 [monthly]
Completed PHASE3
-
Feb 2017 — Jun 2017 [monthly]
Completed PHASE3
-
Jan 2017 — Feb 2017 [monthly]
Completed PHASE3
First recorded
Jul 2009
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Regeneron Pharmaceuticals
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Ahmedabad, India , Bangalore, India , Benoni, South Africa , Berlin, Germany , Bloemfontein, South Africa , Breyten, South Africa , Cape Town, South Africa , Changhua, Taiwan , Dalin Town, Taiwan , Denpasar, Indonesia and 51 more locations